Tumori Journal’s Post

Delighted to share that our review article "Organoid-based Precision Medicine in Pancreatic Cancer" is officially out! 🌟 We delve into how patient-derived organoids are transforming the fight against one of the most challenging cancers by bridging the gap between in vitro models and personalized therapy. Discover the latest insights into the future of precision oncology in #pancreaticcancer: https://lnkd.in/euw-D5N6 #CancerResearch #PrecisionMedicine #Organoids

5 articles suggested by Wafik S. El-Deiry, MD, PhD, FACP Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is a leading expert in oncology and the Director of the Legorreta Cancer Center at Brown University. Known for discovering p21(WAF1) as a key tumor suppressor and his research on therapy resistance, Dr. El-Deiry recently shared a selection of must-read articles on X.🧬 Check them out to stay updated on the latest in cancer research and drug development! https://lnkd.in/dgMwNzgn Authors: Ruiwen Zhang Shayla Mosley Mustafa Sibai #Cancer #CancerResearch #Medicine #Health #BreastCancer #ColorectalCancer #CancerRisk #RiskFactors #Oncology #OncoDaily

The complexity of cancer demands advanced research models. PDX models in humanized immune systems offer the precision researchers need to evaluate next-generation therapies. These tools unlock insights into tumor-immune interactions that traditional models can’t provide. Read our blog to see how this approach could elevate your oncology studies: The Importance of Conducting PDX Oncology Studies in a Humanized Immune System https://hubs.li/Q03014RB0 #PDXmodels #CancerResearch #TD2 #HumanizedMice

Hello LinkedIn #PreclinicalCancerTherapeuticDevelopment (like that hashtag will ever be searched for) Scientists. Are you using #PDX models? Do the models have a #HumanizedImmuneSystem? If not (or even if you do), might I suggest you check out our Translational Drug Development (TD2)'s latest blog post? Drop a comment, DM, or email (mkoratich@TD2Inc.com) if you would like to go even deeper.

As ESMO - European Society for Medical Oncology 2024 concludes, we’re highlighting the top companies that made a mark in oncology. From innovative treatments to impactful clinical trials, these leaders have been pivotal in advancing cancer research and therapies. For more detailed insights, check out LARVOL CLIN here 🔗 https://bit.ly/47krWpH. #ESMO24 #Oncology #ClinicalTrials #CancerResearch #LARVOL #CancerData

Latin America Conference on Lung Cancer will start tomorrow. Discover advancements in #lungcancer therapies, encompassing ongoing clinical trials and comprehensive insights into preclinical and early clinical breakthroughs.  Gain invaluable perspectives on addressing critical disparities in the region, arming yourself with actionable insights to drive change and enhance patient outcomes. If you would like to find information on similar events in one place, visit our Calendar of medical conferences, where you can filter events by date, location and cancer indications: https://lnkd.in/dnnmN4hD #oncology #medicalconference

Breakthrough Computational Model Sheds New Light on Pancreatic Cancer Precursor Lesions A recent study using a computational model has shown that pancreatic precursor lesions (PanIN) are more common and larger than previously thought, offering new perspectives on their progression to cancer. By analyzing over 1,000 PanINs with advanced 3D mapping, the research opens the door for improved early detection and prevention of pancreatic cancer. https://lnkd.in/dY89TtxA National Cancer Institute (NCI) Ashley Kiemen #Cancer #CancerResearch #PancreaticCancer #Medicine #CancerPrevention #EarlyDetection #Health #Oncology #OncoDaily

📰 #UpdateYourRefs ⚡New publication in The Lancet Oncology presenting the results of #ENZA-p Phase 2 Trial on 162 patients with metastatic castration-resistant #prostate cancer from 15 Australian hospitals. It reveals that combining #enzalutamide with [177Lu]Lu-PSMA-617 significantly improves the outcomes compared to enzalutamide alone, raising the median “prostate-specific antigen (PSA) progression-free survival” from 7.8 months to 13.0 months. ➡ https://lnkd.in/eAcSMRfG Louise Emmett #CancerResearch, #ScienceNews, #MedicalResearch, #Cancer, #HealthcareAdvances, #ProstateCancer #LancetOncology #NuclearMedicine

𝗧𝗵𝗮𝗻𝗸𝘀 to everyone who joined us at the 𝗨𝗞 & 𝗜𝗿𝗲𝗹𝗮𝗻𝗱 𝗣𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗕𝗿𝗮𝗰𝗵𝘆𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 on Friday! 🙌 We had a 𝗴𝗿𝗲𝗮𝘁 𝗱𝗮𝘆 and enjoyed the 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝗳𝘂𝗹 𝗱𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 with all of you.💡Thanks go out to our local partners at Oncology Systems Limited as well. Looking forward to the next joint event! The 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗲 once again showed the 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗿𝗼𝗹𝗲 that 𝗟𝗗𝗥 𝗯𝗿𝗮𝗰𝗵𝘆𝘁𝗵𝗲𝗿𝗮𝗽𝘆 plays in the treatment of 𝗽𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗰𝗮𝗻𝗰𝗲𝗿. It is an 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝗺𝗼𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 option for patients with 𝗹𝗼𝘄 𝘁𝗼 𝗳𝗮𝘃𝗼𝗿𝗮𝗯𝗹𝗲-𝗶𝗻𝘁𝗲𝗿𝗺𝗲𝗱𝗶𝗮𝘁𝗲 𝗿𝗶𝘀𝗸 localized prostate cancer and can be 𝗰𝗼𝗺𝗯𝗶𝗻𝗲𝗱 𝘄𝗶𝘁𝗵 𝗘𝗕𝗥𝗧 to improve outcomes for 𝗵𝗶𝗴𝗵𝗲𝗿 𝗿𝗶𝘀𝗸 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 🏥 If you want to 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲, 𝗰𝗵𝗲𝗰𝗸 𝗼𝘂𝘁 𝗼𝘂𝗿 𝗯𝗹𝗼𝗴, where we've got some interesting posts and 𝗲𝘅𝗽𝗲𝗿𝘁 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 on the topic. Just follow the 𝗹𝗶𝗻𝗸 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗺𝗺𝗲𝗻𝘁𝘀 🔽 #Brachytherapy #UroOncology #ProstateSeedTherapy #RadiationTherapy #RadiationOncology  

🎥 Now streaming on high5oncologyTV: A deep dive into the latest data from #SABCS2024 on advanced breast cancer. 🔍 Discover innovative systemic therapies, promising antibody-drug conjugates, and the most impactful study results. 💡 How will these findings influence clinical practice? Learn more in our expert panel discussion! 📺 Watch the video: https://lnkd.in/eHfVb4iA 📌 #AdvancedBreastCancer #SABCS2024 #high5oncologyTV #MetastaticBreastCancer #TherapyOptions #BreastCancer #CancerTreatment